Effect of Hormone Therapy on Renal Function
Sponsored by University of Colorado, Denver
About this trial
Last updated 2 years ago
Study ID
Status
Type
Placebo
Accepting
Trial Timing
Ended 2 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Identify as transgender
- Age 17-30 years (inclusive)
- Plan to start gender affirming hormone therapy (testosterone or estradiol) clinically in ≤ 1 months and remain on for at least 3 months
Exclusion Criteria
- Cognitive, psychiatric or physical impairment resulting in inability to tolerate the study procedures (e.g. intellectual disability, schizophrenia, hallucinations)
- Type 1 or Type 2 diabetes
- Chronic kidney disease, or eGFR <60ml/min/1.73m2 by CKD-EPI formulation
- Uncontrolled hypertension (resting BP ≥ 140/90 mm/Hg)
- Allergy to shellfish, iodine or iohexol
- Currently taking: sulfonamides, procaine, thiazolesulfone and probenecid (renal clearance measurements of PAH cannot be made accurately if individuals are on these medications)
- Prior gender affirming hormone therapy use
- Prior gonadectomy
- Pregnancy